5.5 months; HR, 0.80; 95% CI, 0.69–0.92;P= .0025).In the PD-L1–positive population, PFS was improved with the addition of atezolizumab (median PFS, 7.5 months vs.
5 months; HR, 0.62; 95% CI, 0.49–0.78;P< .001).Adverse events occurred as expected.
Adverse events that were potentially immune-related were more frequent in the atezolizumab arm.
In the ITT population, PFS was improved with the addition of atezolizumab (median PFS, 7.2 months vs.
5.5 months; HR, 0.80; 95% CI, 0.69–0.92;P= .0025).
In the PD-L1–positive population, PFS was improved with the addition of atezolizumab (median PFS, 7.5 months vs.